Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
<p>Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Repre...
Đã lưu trong:
| Tác giả chính: | |
|---|---|
| Tác giả khác: | , , , , , , , , , , , , , , , , , |
| Được phát hành: |
2025
|
| Những chủ đề: | |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| _version_ | 1849927633688592384 |
|---|---|
| author | Evan C. Chen (15054014) |
| author2 | Helen Gandler (15054017) Isidora Tošić (15054020) Geoffrey G. Fell (15054023) Ashlee Fiore (15054026) Olga Pozdnyakova (15054029) Daniel J. DeAngelo (15031959) Ilene Galinsky (15054032) Marlise R. Luskin (15054035) Martha Wadleigh (15054038) Eric S. Winer (15054041) Rebecca Leonard (15054044) Kelsey O'Day (15054047) Adrienne de Jonge (15054050) Donna Neuberg (15038318) A. Thomas Look (14951403) Richard M. Stone (15054053) David A. Frank (14961075) Jacqueline S. Garcia (15043140) |
| author2_role | author author author author author author author author author author author author author author author author author author |
| author_facet | Evan C. Chen (15054014) Helen Gandler (15054017) Isidora Tošić (15054020) Geoffrey G. Fell (15054023) Ashlee Fiore (15054026) Olga Pozdnyakova (15054029) Daniel J. DeAngelo (15031959) Ilene Galinsky (15054032) Marlise R. Luskin (15054035) Martha Wadleigh (15054038) Eric S. Winer (15054041) Rebecca Leonard (15054044) Kelsey O'Day (15054047) Adrienne de Jonge (15054050) Donna Neuberg (15038318) A. Thomas Look (14951403) Richard M. Stone (15054053) David A. Frank (14961075) Jacqueline S. Garcia (15043140) |
| author_role | author |
| dc.creator.none.fl_str_mv | Evan C. Chen (15054014) Helen Gandler (15054017) Isidora Tošić (15054020) Geoffrey G. Fell (15054023) Ashlee Fiore (15054026) Olga Pozdnyakova (15054029) Daniel J. DeAngelo (15031959) Ilene Galinsky (15054032) Marlise R. Luskin (15054035) Martha Wadleigh (15054038) Eric S. Winer (15054041) Rebecca Leonard (15054044) Kelsey O'Day (15054047) Adrienne de Jonge (15054050) Donna Neuberg (15038318) A. Thomas Look (14951403) Richard M. Stone (15054053) David A. Frank (14961075) Jacqueline S. Garcia (15043140) |
| dc.date.none.fl_str_mv | 2025-11-25T13:01:56Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706835 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_S2_from_Targeting_MET_and_FGFR_in_Relapsed_or_Refractory_Acute_Myeloid_Leukemia_Preclinical_and_Clinical_Findings_and_Signal_Transduction_Correlates/30706835 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research |
| dc.title.none.fl_str_mv | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Representative flow cytometry histograms are shown in B. Reverse transcription-PCR showing decreased expression of CISH, a downstream target of STAT5, is displayed in C. Abbreviations: U = unstained; FGFRi = the FGFR inhibitor LY2874455.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_84b75c0880f0ea364bf702b49db82e9e |
| identifier_str_mv | 10.1158/1078-0432.30706835 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706835 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction CorrelatesEvan C. Chen (15054014)Helen Gandler (15054017)Isidora Tošić (15054020)Geoffrey G. Fell (15054023)Ashlee Fiore (15054026)Olga Pozdnyakova (15054029)Daniel J. DeAngelo (15031959)Ilene Galinsky (15054032)Marlise R. Luskin (15054035)Martha Wadleigh (15054038)Eric S. Winer (15054041)Rebecca Leonard (15054044)Kelsey O'Day (15054047)Adrienne de Jonge (15054050)Donna Neuberg (15038318)A. Thomas Look (14951403)Richard M. Stone (15054053)David A. Frank (14961075)Jacqueline S. Garcia (15043140)CancerTherapeutic Research and DevelopmentClinical Research and TrialsClinical Trial ResultsPhase I clinical trialsDrug TargetsProtein kinase & phosphatase drug targetsHematological CancersLeukemiasPharmacologyPharmacokinetics and pharmacodynamicsPrecision MedicineSmall Molecule AgentsKinase inhibitorsTranslational Research<p>Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Representative flow cytometry histograms are shown in B. Reverse transcription-PCR showing decreased expression of CISH, a downstream target of STAT5, is displayed in C. Abbreviations: U = unstained; FGFRi = the FGFR inhibitor LY2874455.</p>2025-11-25T13:01:56ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706835https://figshare.com/articles/figure/Figure_S2_from_Targeting_MET_and_FGFR_in_Relapsed_or_Refractory_Acute_Myeloid_Leukemia_Preclinical_and_Clinical_Findings_and_Signal_Transduction_Correlates/30706835CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307068352025-11-25T13:01:56Z |
| spellingShingle | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Evan C. Chen (15054014) Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research |
| status_str | publishedVersion |
| title | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_full | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_fullStr | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_full_unstemmed | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_short | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_sort | Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| topic | Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research |